Subtenon Injection of Autologous Platelet-Rich Plasma in Retinitis Pigmentosa: Is It a New Therapeutic Option?
Open Access
- 1 January 2020
- journal article
- research article
- Published by Scientific Research Publishing, Inc. in Open Journal of Ophthalmology
- Vol. 10 (01), 77-88
- https://doi.org/10.4236/ojoph.2020.101010
Abstract
Purpose: Growth factors (GFs) and neurotrophins can decelerate retinal degeneration. This study aimed to investigate the safety, efficacy and durability of subtenon injections of autologous platelet-rich plasma (aPRP) which is a rich source of GFs in retinitis pigmentosa (RP) patients. Methods: 154 eyes of 77 RP patients with various degrees of narrowed visual field were investigated in this study. Each patient received three injections with 4-week intervals and followed for at least 12 months. The examinations and the tests were obtained before the injection, 1 month after the third injection and every 3 months during the study. The primary aim was to evaluate the effects of aPRP on visual acuity (VA) and visual functions, the second aim was to estimate the duration of the therapy effect and the need for additional aPRP injection. Results: Median age of the 77 RP patients was 35.2 ± 13.9 years. All of the eyes received 3 monthly bilateral subtenon aPRP injections. Of these patients 26 received an additional one, 12 received additional two and 1 patient received additional 3 injections with 3-month interval. There were no significant ocular or systemic side effects. The mean baseline VA was 0.22 ± 0.18 Snellen lines. It improved to 0.31 ± 0.19 following three aPRP injections, which was statistically significant. At the end of the study period, the mean VA was 0.27 ± 0.22 Snellen lines. Conclusion: The subtenon injection of aPRP might be an effective therapy and might have a positive influence in the preservation of visual functions and visual acuity of RP patients.Keywords
This publication has 32 references indexed in Scilit:
- Allogeneic Serum Eye Drops for the Treatment of Dry Eye Patients with Chronic Graft-Versus-Host DiseaseJournal of Ocular Pharmacology and Therapeutics, 2012
- Current advances in using neurotrophic factors to treat neurodegenerative disordersTranslational Neurodegeneration, 2012
- CNTF and retinaProgress in Retinal and Eye Research, 2012
- Longitudinal Study of Cone Photoreceptors during Retinal Degeneration and in Response to Ciliary Neurotrophic Factor TreatmentInvestigative Ophthalmology & Visual Science, 2011
- Why Some Photoreceptors Die, While Others Remain Dormant: Lessons FromRPE65andLRATAssociated Retinal DystrophiesOphthalmic Genetics, 2010
- Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucomaProceedings of the National Academy of Sciences of the United States of America, 2009
- ISCEV Standard for full-field clinical electroretinography (2008 update)Documenta Ophthalmologica, 2008
- Nerve growth factor involvement in the visual system: implications in allergic and neurodegenerative diseasesCytokine & Growth Factor Reviews, 2004
- Autologous serum application in the treatment of neurotrophic keratopathy*1Ophthalmology, 2004
- Autologous platelets as a source of proteins for healing and tissue regenerationThrombosis and Haemostasis, 2004